• Citer

Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients.

par Rothé, Françoise ;Lambertini, Matteo ;Goldrat, Ornite ;Maetens, Marion ;Bareche, Yacine ;Blanc, Jeremy ;Rouas, Ghizlane ;Larsimont, Denis ;Sotiriou, Christos ;Ignatiadis, Michail ;Demeestere, Isabelle
Référence Frontiers in oncology, 11, page (686625)
Publication Publié, 2021-12-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Current fertility preservation strategies for young breast cancer patients planning a future motherhood include the association of controlled ovarian stimulation with the aromatase inhibitor letrozole (let-COS) to harvest mature oocytes while maintaining low estradiol levels. Despite this is a widely adopted protocol, the safety of let-COS on breast cancer outcomes has been poorly investigated and its use remains off-label. We assessed the safety of let-COS in breast cancer patients using circulating tumor DNA (ctDNA) as a surrogate biomarker of disease recurrence.